Literature DB >> 11573490

Riluzole for motor neurone disease. Reply from chairman of appraisal committee at NICE.

D Barnett.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11573490      PMCID: PMC1121145     

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

1.  Riluzole for motor neurone disease. Ambiguous diagnostic criteria mean that wide variations in elgibility may still persist.

Authors:  R Stewart
Journal:  BMJ       Date:  2001-05-26

2.  Riluzole for motor neurone disease. More trials are needed.

Authors:  J Sandercock; A Burls; C Hyde; A Fry-Smith; P Barton; S Bryan; A Stewart
Journal:  BMJ       Date:  2001-05-26

3.  An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole.

Authors:  M Riviere; V Meininger; P Zeisser; T Munsat
Journal:  Arch Neurol       Date:  1998-04

Review 4.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Authors:  R G Miller; J D Mitchell; D H Moore
Journal:  Cochrane Database Syst Rev       Date:  2000

5.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.

Authors:  L Lacomblez; G Bensimon; P N Leigh; P Guillet; V Meininger
Journal:  Lancet       Date:  1996-05-25       Impact factor: 79.321

6.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.

Authors:  G Bensimon; L Lacomblez; V Meininger
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

  6 in total
  1 in total

1.  Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?

Authors:  Tom Walley
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.